🇺🇸

M&A Activity

· daily

US Merger & Acquisition SEC Filings — April 07, 2026

The April 7, 2026, USA M&A & Takeover Activity stream reveals a robust wave of transaction completions and progressions, with 8 out of 15 filings announcing deal closures including high-profile takeovers (Hologic by Blackstone/TPG at up to $79/share), acquisitions (Runway of SWK boosting assets to $1.2B pro forma), and divestitures (CVD Equipment's SDC sale for $16.9M cash). SPAC activity dominates the first 7 new filings, featuring 5 deadline extensions or combination advancements (Aquaron, Athena, Real Asset-IQM, Alchemy-Cartiga, Haymaker non-redemption), signaling sustained merger momentum amid redemption pressures. Period-over-period pro forma trends show mixed results: revenue declines in Ginkgo (-22% to $132.7M for 2025 post-Biosecurity spin) and TCW Direct Lending (-70% NII to $30M), contrasted by Runway's healthcare exposure doubling to 32% and stable NAVs in TCW exchanges. Positive sentiments prevail (9/15 filings), with capital deployed into strategic assets (Supernus psychiatry pipeline, Northwest CDMO), enhancing focus but highlighting profitability challenges in biotech. Portfolio-level implications favor monitoring SPAC catalysts for de-SPAC pops and post-merger integration risks in finance/healthcare sectors.

15 high priority 15 total filings
· daily

US Merger & Acquisition SEC Filings — April 06, 2026

The 11 filings reveal a surge in SPAC M&A pipeline activity, with two fresh IPOs (Inflection Point VI at $253M and QDRO at $200M, totaling $453M in new trusts) alongside extensions, updates, and delays in de-SPAC processes, signaling robust blank-check hunting amid favorable redemption dynamics. Completed takeovers dominate high-materiality events: Howmet's $1.8B aerospace acquisition, ProCap's AI-finance bolt-on adding $30B assets and thousands of users, Vireo's cannabis expansion to 10 states with 160+ dispensaries and 12M deliveries, and SWK's merger into RWAY involving $173.5M cash + 6.33M shares issued. Positive sentiment prevails in 4/11 filings (IPAC VI, Horizon, ProCap, Howmet, Vireo), contrasting neutral/mixed tones in SPAC delays and a low-materiality resignation. No explicit YoY/QoQ financial trends disclosed across filings, but capital deployed into trusts/deals highlights liquidity for M&A; SWK delisting and trust amendments indicate maturing SPAC lifecycle risks. Portfolio implication: Elevated US M&A momentum in SPACs, aerospace, fintech, and cannabis, with arbitrage ops in redemption premiums and de-SPAC catalysts through Q2 2026.

11 high priority 11 total filings
· daily

US Merger & Acquisition SEC Filings — April 03, 2026

The six SPAC filings reveal a bifurcated US M&A landscape with fresh momentum in de-SPAC transactions and IPOs contrasted by compliance distress and financing strains; Crown Reserve's Carvix merger and Future Money's $115.6M IPO (including $112M public + $3.04M private placement) signal robust deal activity, while JENA's NYSE non-compliance and DMII's sponsor transition highlight sector headwinds. No explicit YoY/QoQ financial trends or operational metrics reported across filings, but forward-looking timelines cluster catalysts in 45 days (JENA plan), 4-6 months (DMII deal execution), and 3-year earnouts (Crown). Insider activity absent; capital allocation focused on trust deposits (Future Money) and debt amendments (Inflection Point note up 14% QoQ from $700k to $800k). High materiality developments (avg 7.5/10) underscore SPAC revival potential amid regulatory risks, with positive sentiment in 2/6 filings driving takeover opportunities. Portfolio-level pattern: 4/6 newly published filings show financing/de-SPAC urgency, implying accelerated M&A timelines versus stagnant peers.

6 high priority 6 total filings
· daily

US Merger & Acquisition SEC Filings — April 02, 2026

A surge in US M&A and takeover activity is evident across 20 filings on April 2, 2026, with 12 completions or announcements including strategic acquisitions in energy, pharma, retail, investment management, avionics, and buses, alongside 2 divestitures of non-core assets netting $24.8M and $70M cash respectively. SPACs dominate with 7 filings focused on unit separations, extensions, merger approvals, and amendments, signaling sustained deal hunting amid low redemptions (e.g., 1,153 shares in Tech & Tele). Positive sentiment prevails in 10/20 filings (50%), driven by accretive deals adding capacity (395MW Kodiak), AUM ($1.63B Bimini), revenue streams (Abundia Q2), and portfolio diversification, while mixed/neutral tones in divestitures and administrative updates. Period-over-period data limited but notable: Ashford pro forma revenue -1.6% YoY to $1.087B but net loss improved 16.5% to $157M excluding underperformer. No insider trading reported; forward-looking highlights include immediate accretion (Kodiak), Q2 revenue (Abundia), 2027 earnouts (Crown), and integration catalysts. Portfolio-level: M&A valuations range $200M-$1B EV, emphasizing bolt-ons for growth; implications point to sector consolidation in energy/industrials, SPAC revival.

20 high priority 20 total filings
· daily

US Merger & Acquisition SEC Filings — April 01, 2026

A surge in US M&A and takeover activity dominates the 30 filings, with 12 bank/regional financial mergers completing on April 1, 2026 (e.g., CWBC/UBFO at $185.5M, SPFI/BOH adding $744M assets, FirstSun/First Foundation creating $20.4B asset entity), signaling aggressive consolidation in regional banking amid $5B-$34B combined asset footprints. SPAC ecosystem thrives with 6 IPO pricings/LOIs (e.g., Future Money $100M, QDRO $200M) and preparatory restructurings, while divestitures (8 cases) boost pro forma cash (e.g., Duke $2.48B proceeds, CHS $459M gain) but compress revenues (avg -15% YoY pro forma across 7 with data). Spin-offs like Versigent (Aptiv carve-out, $8.8B rev +3% YoY, EBITDA to expand 200bps over 3yrs) and mixed JV/deals (Lands' End $300M IP swap) highlight portfolio optimization. Portfolio-level trends show pro forma net income gains from one-time sale gains (avg +100% in 5 cases) offsetting op rev declines (-1.8% to -55%), with positive sentiment in 70% of filings. Implications: Regional banks gain scale for efficiency; watch summer 2026 systems conversions as catalysts; SPACs signal dry powder for de-SPAC waves.

30 high priority 30 total filings
· daily

US Merger & Acquisition SEC Filings — March 31, 2026

Across 10 US SEC filings focused on M&A and takeover activity in the period ending March 31, 2026, a surge in deal completions dominates, including 4 de-SPAC mergers/IPOs/amendments (Trailblazer/Cyabra, Soulpower, Spartacus, Inflection Point, Live Oak), 3 acquisitions (SCYNEXIS, Spire, Oramed/Lifeward), 2 divestitures (BrightSpring, Oramed), and 1 share authorization (Mobivity), signaling robust M&A momentum in biotech, utilities, health services, and SPACs. No explicit period-over-period financial declines reported; instead, themes of portfolio optimization via divestitures and bolt-on acquisitions highlight strategic refocusing without margin compression or YoY revenue drops noted. SPAC activity is particularly hot with 5 filings, pro forma valuations up to $8.5B (Soulpower), and trading commencements imminent. Positive sentiment prevails in 7/10 filings (avg materiality 8.5/10), with forward-looking catalysts like Phase 2 trials (SCYNEXIS Q4 2026) and EPS growth targets (Spire 5-7%). Mixed/neutral tones in Soulpower (closing delay), Live Oak, and Mobivity flag execution risks. Implications: Investors should prioritize post-deal liquidity events and pipeline readouts for alpha, as capital allocation favors growth via M&A over buybacks/dividends.

10 high priority 10 total filings
· daily

US Merger & Acquisition SEC Filings — March 30, 2026

The March 30, 2026, filings reveal heightened USA M&A and takeover activity, with 4 major acquisitions/divestitures (Leidos $2.4B, Addentax control stake, Bitmine blockchain assets, Aimco $455M property sale) signaling strategic expansion in energy infrastructure, fashion, crypto staking, and REIT portfolio optimization. SPACs dominate the rest, with extensions (Constellation to April 29), redemptions (ASPAC shares down 71% YoY post-Oct), resignations (UY Scuti CFO), and voting (Relativity), reflecting ongoing deal pursuits amid deadline pressures. Positive sentiment prevails in 4/8 filings (50%), mixed in Aimco due to pro forma revenue decline 33% to $92.6M for 2025 despite liquidity boost (cash +$547.5M, debt -to $457.3M). No insider trading or dividend changes noted across filings, but transaction terms highlight deferred payments/earnouts (Bitmine $14M deferred + $11.8M earnout). Portfolio trend: Acquirers gaining scale (Leidos doubling energy presence), SPACs managing liquidity for catalysts; watch SPAC merger votes for takeover upside.

8 high priority 8 total filings
· daily

US Merger & Acquisition SEC Filings — March 27, 2026

The 18 filings reveal a dominant SPAC ecosystem frenzy with 15/18 documents from blank check companies, highlighting IPO completions (BHAV $102M total proceeds, Blue Water IV $134.25M, TRG partial over-allotment to $206.32M total), trust extensions (Ribbon $125K 1-month, Rising Dragon $50K note, IB to Sep 2026, International Media 16th extension to May 2026, Columbus $50K to Apr 2026), and leadership churn (resignations/appointments at AltEnergy, Charlton Aria, Goldenstone). Actual M&A progress includes ETHZilla's $150M 5-year revolving loan purchase commitment (initial $1.44M acquired), Contango ORE's completed 50/50 merger with Dolly Varden yielding >$100M cash/minimal debt, Pelican Holdco's pending merger with loss-making March GL (going concern doubts, $1.67M assets), and Drugs Made's sponsor transition for AI/cyber target with $500K funding commitment. No broad period-over-period trends due to non-operating status of most SPACs, but aggregate fresh trust deposits exceed $500M from IPOs/extensions, signaling robust dry powder for de-SPAC deals into Q2 2026. Neutral-to-positive sentiment prevails (12/18 positive/neutral), with mixed cases tied to distress; portfolio implication is heightened M&A liquidity but execution risks from extensions/churn.

18 high priority 18 total filings
· daily

US Merger & Acquisition SEC Filings — March 26, 2026

The 8 filings highlight intense SPAC maneuvering amid M&A completions in niche sectors like crypto blockchain and industrial/pharma mergers, with 5/8 filings from blank-check companies (Soulpower, Launch One, Haymaker, IB, Metal Sky) showing extension efforts, financings, and governance changes versus 3 actual deal closures (Atlantic, Crypto Co, Enzon). Key trends include heavy SPAC redemptions (e.g., IB's $7.9M outflow leaving $8.2M trust) and sponsor support via notes/preferred stock, signaling prolonged hunts for targets; no broad YoY/QoQ financial trends reported but capital raises average ~$1.25M principal across notes/preferred for working capital/BC. Positive catalysts emerge from Crypto Co's milestone-based IP acquisition with 2026 blockchain launch and Enzon's all-stock merger (45/55 ownership split), boosting interoperability and operational scale. Mixed sentiment prevails (3 neutral, 2 positive, 1 mixed) with materiality skewed high (5/8 at 7-9/10) on deal-related filings, implying near-term volatility in SPACs but alpha in completed M&A. Portfolio-level pattern: SPACs face redemption pressures (1/5 with quantified $7.9M drain) versus accretive deals with no upfront dilution.

8 high priority 8 total filings
· daily

US Merger & Acquisition SEC Filings — March 25, 2026

A surge in US M&A and takeover activity dominates the week's filings, with 7 events spanning SPAC milestones (IPOs, amendments, unit separations), strategic acquisitions in food (FDP $285M Del Monte assets), cannabis (Vireo <4x EBITDA dispensaries/manufacturing), medtech (Lifeward amendment), and a mining divestiture (Hecla $160M cash + 65.8M shares + $321M contingent). Positive sentiment prevails in 5/7 filings (71%), with high materiality (avg 8/10) signaling portfolio-level M&A acceleration amid SPAC resurgence; no explicit YoY/QoQ revenue trends but deal-driven growth implied via platform expansions and low-multiple buys. Key developments include Hecla's deleveraging ($263M note redemption April 9) and FDP's brand reunion after 40 years, enhancing efficiency but flagging integration risks. Cross-company patterns show capital recycling (divest-to-acquire/reinvest), SPAC dry powder influx ($125M Blue Water IPO), and forward-looking catalysts like earnouts (Athena 25.5M shares) and dispensary scaling (Vireo to 75+). Implications: Bullish for M&A targets and post-deal synergies, watch SPAC closings for de-SPAC pops; sector tailwinds in cannabis/food/mining divestitures boost shareholder value via accretive deals.

7 high priority 7 total filings
· daily

US Merger & Acquisition SEC Filings — March 24, 2026

The 9 filings reveal a bifurcated US M&A landscape dominated by SPAC activity (6/9 filings), with progress via PIPE financings, non-redemption agreements, and administrative setups contrasting sharply against Oak Woods' imminent delisting for failing to complete a business combination within 36 months. Completed deals in operating companies show mixed pro forma impacts: LSI Industries' $325M acquisition boosts combined TTM revenue to $864M (+46% vs LSI standalone $593M) and EBITDA margin to 11% (from 9.7%), while Cardlytics' $25.4M divestiture narrows 2024 net losses 79% to $(40.4M) despite 8-9% revenue declines YoY. Playboy's JV sale secures $122M in contracted cash through 2033, enabling debt paydown and immediate earnings accretion. Period-over-period trends highlight profitability improvements post-transaction (e.g., Cardlytics net loss per share to $(1.72) in 2025) amid revenue softness, signaling portfolio-level deleveraging and strategic refocus. No insider trading or dividend/buyback changes noted across filings, but capital allocation leans toward debt reduction (Playboy) and acquisition funding via debt/equity (LSI). SPAC advancements build toward catalysts like S-4 filings and closings, while distress in one underscores sector risks.

9 high priority 9 total filings
· daily

US Merger & Acquisition SEC Filings — March 24, 2026

The 9 filings reveal robust M&A and takeover activity dominated by SPACs (6/9 filings) facing mixed fortunes, including PIPE financings, non-redemption support, administrative deals, but also delisting risks, alongside operating company divestitures and acquisitions showing pro forma financial improvements. Key period-over-period trends include revenue declines in divested units (Cardlytics: 2025 revenue down 9% pro forma to $212.3M) but narrower net losses (79% improvement in 2024 to $(40.4M)), EBITDA margin expansion via accretive deals (LSI: combined 11% from 9.7%), and secured future cash flows (Playboy: $122M contracted through 2033). Critical developments like LSI's $325M acquisition and Playboy's $15M JV sale signal strategic portfolio optimization, while SPAC challenges (Oak Woods delisting March 25, 2026) highlight deadline pressures post-36 months. Portfolio-level patterns show 3/9 with positive pro forma metrics (narrower losses, higher EBITDA), contrasting SPAC neutral/negative sentiment; sector themes point to industrials/licensing M&A strength amid SPAC fatigue. Implications favor monitoring post-deal integrations and SPAC closings for near-term catalysts, with asset-light shifts boosting returns.

9 high priority 9 total filings
· daily

US Merger & Acquisition SEC Filings — March 23, 2026

The 10 filings reveal heightened US M&A and takeover activity dominated by SPACs (7/10 filings), with extensions, approvals, and high redemptions signaling persistent deal momentum amid liquidity pressures; actual sector M&A includes mining consolidation (Coeur-New Gold boosting 2026 gold production guidance 80% YoY from 419k oz to 680-815k oz), reinsurance divestiture (FG Nexus), crowdfunding expansion (StartEngine-Vinovest adding $140-150M AUM), and governance tweaks post-acquisition (Exact Sciences). Period-over-period trends show SPAC trust deposits for extensions (YHN $150k) contrasting low balances (TETE $142k signaling redemptions), while Coeur's reserves integration extends mine life to 2032-2035 with strong FCF projections. Capital allocation shines in Coeur's $750M buyback and inaugural $0.02/share dividend vs prior $400M facility upgrade to $1B revolver. Overarching themes: SPAC resilience via extensions/name changes (Goldenstone to Chi Special) but delisting risks (Bayview); positive sentiment in 6/10 filings drives alpha in mining/alts, mixed in SPACs due to redemptions (Crane 19.4M shares/$201M). Portfolio implication: Favor completed M&A with guidance upside over pre-merger SPACs; monitor March 26-31 catalysts for volatility.

10 high priority 10 total filings
· daily

US Merger & Acquisition SEC Filings — March 20, 2026

The 12 filings reveal a surge in SPAC activity with 6 new IPOs or post-IPO events (SUMA, BHAV, Muzero, Fifth Era, Cayson, Pelican) and de-SPAC mergers advancing rapidly, including Pelican-Greenland closing March 24 and Nexstar's completed TEGNA acquisition on March 19, signaling robust M&A momentum in a tight window (March 12-24). Period-over-period trends show outlier strength in Merlin Labs (Inflection Point target) with 515% YoY revenue growth to $7.6M despite 35% wider net losses to $74.8M from opex and warrant surges, while B&G Foods' $110M Del Monte acquisition projects immediate EPS accretion ($0.08-0.12) at 5.5x EBITDA multiple. High redemptions (63% or 7.56M shares, $77.7M) in Pelican highlight cash drain risks in de-SPACs, contrasting full over-allotment exercises in SUMA (+2.25M units) and BHAV's $100M IPO. Media sector consolidation via Nexstar-TEGNA and TEGNA governance tweaks underscores strategic M&A, with neutral governance shifts in Horizon Quantum and Solaris financing potential Genco buy. Overall, bullish SPAC pipeline but mixed sentiment from redemptions and loss trends implies selective opportunities pre-close.

12 high priority 12 total filings
· daily

US Merger & Acquisition SEC Filings — March 19, 2026

The USA M&A & Takeover Activity stream reveals intense SPAC activity across 10/12 filings, with new IPOs (Metals Acquisition Corp II $230M, Praetorian $253M total), over-allotment exercises, and multiple BCA extensions (Pyrophyte 5th amendment to Apr 2027, Blue incentive pool to 8%), signaling prolonged deal hunts amid market appetite for fresh capital. Ashford Hospitality Trust's $56.8M hotel sale drove pro forma revenue decline of 1.5% YoY to $1.15B (YE2024) but improved net loss 17% to $68.5M, reflecting deleveraging. Battalion Oil's all-stock acquisition added 7,090 acres and 30 drilling locations, expanding contiguous holdings 35% to 27,097 acres. No insider trading reported; capital allocation focuses on trust funding (Constellation note to $5.25M) and debt repayment. Period trends show stable/no declines in most SPACs, mixed in hospitality; forward deadlines cluster Q2 2026-Q1 2027, building catalyst calendar. Portfolio-level: 7/12 neutral sentiment, 3 positive IPO/amendments, implying SPAC resilience but extension fatigue risk.

12 high priority 12 total filings
· daily

US Merger & Acquisition SEC Filings — March 18, 2026

The 13 filings reveal robust M&A and SPAC activity centered on business combinations, extensions, and niche sector acquisitions, with 10/13 involving SPACs showing persistence amid challenges like high redemptions (Voyager: 25.2M shares redeemed, trust at $885k) and one termination (Quartzsea due to CSRC delays). Positive divestitures and acquisitions dominate non-SPAC activity: TriMas $1.45B Aerospace sale yields $1.2B for growth/buybacks; BlockchAIn completes combo with $22.9M rev/$5.7M NI data center targeting AI expansions 2026-27; cannabis M&A surges via Grown Rogue (60% cost savings, Q2 2026 ops) and Global Asset (license options). No period-over-period declines reported across filings (e.g., BlockchAIn 2024 metrics strong, TriMas no quantitative drops); forward looks cluster in Q2-Q4 2026 for operations/expansions. Portfolio trends: Neutral routine SPAC mechanics (unit separations in 2, extensions in 3) mask bullish niche growth in AI/HPC, cannabis, packaging; bearish regulatory hurdles in PRC-related deals. Implications: Capital recycling fuels buybacks/acquisitions; monitor SPAC closings for dilution risks, alpha in post-combo trading (e.g., AIB ticker).

13 high priority 13 total filings
· daily

US Merger & Acquisition SEC Filings — March 17, 2026

The 15 filings reveal a robust wave of M&A and takeover activity dominated by SPAC/deSPAC transactions (9/15 filings), with amendments, financings, and adjournments signaling persistent deal-making amid delays. Completed mega-deals include Alexander & Baldwin's $2.3B take-private at $21.20/share, IBM's $11B acquisition of Confluent at $31/share, and Fulgent's $56.9M asset buys, highlighting strong buyer appetite in real estate, tech/AI, and diagnostics. Positive sentiment prevails (8/15 positive, 4 neutral, 3 mixed), with no reported period-over-period financial declines or metric compressions across filings; instead, forward-looking catalysts like Q2 2026 revenue ramps and IND submissions dominate. SPAC extensions (e.g., Israel Acq to Apr 15) and bridge notes indicate capital raises to bridge to closings, while fresh IPOs like GalaxyEdge's $115M raise underscore new liquidity. Portfolio-level pattern: 6/15 filings involve procedural advances (amendments/adjournments) without financial revisions, suggesting stable valuations but timing risks. Overall, bullish M&A momentum implies sector rotation opportunities into targets and acquirers, with catalysts clustered in late March.

15 high priority 15 total filings
· daily

US Merger & Acquisition SEC Filings — March 16, 2026

The March 16, 2026 snapshot reveals a vibrant US M&A and SPAC landscape with 13 filings dominated by blank check company activities (9/13) including IPOs, extensions, unit separations, and de-SPAC announcements, alongside 4 material acquisitions/completions in fitness, defense, and tech sectors. Completed deals like Interactive Strength's $8.75-14.25M Ergatta buyout and Ondas Holdings' Rotron and 4M Defense acquisitions (total ~$5M stock with 30% YoY growth earnouts) highlight strategic expansions without reported financial declines. Pending high-value de-SPACs (Abra at $750M pre-money with $10B AUM target by 2027; GNQ at $500M with Q3 2026 close) signal bullish crypto/TechBio momentum, while SPAC extensions (Bayview 4th of 6, TLGY monthly) indicate prolonged target hunts but no liquidation risks yet. No period-over-period revenue/margin declines or insider selling noted across filings; sentiments skew positive/neutral with materiality peaking at 10/10 for Metals II IPO. Portfolio trend: SPACs represent 70% activity, clustering extensions/adjournments suggesting proxy challenges but robust fundraising ($200M+ Metals II). Implications: M&A acceleration in defense/autonomous systems and digital assets offers near-term catalysts amid stable emerging growth company statuses.

13 high priority 13 total filings
· daily

US Merger & Acquisition SEC Filings — March 13, 2026

The 13 filings reveal a surge in SPAC activity with 7/13 involving blank check companies, including 3 IPOs/pricings (Kensington $230M, SUMA $150M) and extensions/deposit (Inception $12k for 1-month to April 13), signaling robust capital raising for M&A amid a 24-36 month combination windows. M&A completions dominate with IF Bancorp merger finalized at $26.40/share cash (delisting March 13), Aditxt's $36M oncology acquisition, and asset sales like Kaanapali's $19.9M land ($10.3M gain) and Moody REIT's $18.85M hotel disposition, though pro forma sales declines noted in 2 cases. Mixed sentiment in 3 filings highlights pro forma deteriorations (New Mountain net assets -3% to $1.153B, realized losses widened to $155M), but overall positive tone in 6/13 with no YoY/QoQ revenue declines beyond isolated pro formas (-$123k 2024 sales for Kaanapali). No insider trading or capital allocation shifts reported across filings, but forward-looking catalysts cluster in March (delistings, trading starts, closings). Portfolio-level trend: Elevated M&A velocity in SPACs/tech/healthcare vs quieter real estate dispositions; implications include heightened takeover premiums and de-SPAC opportunities, with $230M+ trust accounts positioning energy/tech targets.

13 high priority 13 total filings
· daily

US Merger & Acquisition SEC Filings — March 12, 2026

A surge in US M&A and takeover activity dominates the 10 filings, with 7 announcing or completing strategic acquisitions, SPAC business combinations, or asset sales, reflecting strong deal momentum amid positive sentiment in 8/10 cases. SPACs like Inflection Point IV, Plum IV, and Quetta show advanced progress toward closings via shareholder approvals and support agreements, while traditional M&A includes Laird Superfood's $38.5M Navitas buy and T Stamp's dual cyber deals. No aggregate period-over-period financial trends available across filings due to event-driven nature, but transaction volumes highlight scaling ambitions in nutrition, AI/cybersecurity, and energy. Risks limited to Oak Woods' Nasdaq delisting threat and Ribbon's repeated EGM adjournments signaling proxy hurdles. Portfolio-level pattern: 6/10 filings involve tech/AI/energy targets, implying sector consolidation; actionable now as approvals cluster in March 2026 with Q3 closings ahead.

10 high priority 10 total filings